New research suggests that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who end conventional diet and exercise regimens.
Findings released in a leading medical journal demonstrates that while obese people frequently drop about a fifth of their total mass while on the medication, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"Users buying these medications should be cognizant of the risk of quick rebound weight gain when the medication concludes," cautioned researcher Dr. Susan Jebb.
That rate of recovery suggests a return to starting weight within about a year and a half.
Weighing Therapies
The analysis, which reviewed dozens of studies involving over 9,000 of patients, contrasted the effects of these new drugs with other pills.
Scientists emphasize that people who shed pounds through dieting typically see a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Experts propose the mode of action of the jabs accounts for the amplified regain.
The injections mimic a body's own chemical called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the system to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' leads to hunger is uncontrolled, making overeating a significant risk."
An Ongoing Issue?
The NHS suggest the injections for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, considering the significant potential of weight regain, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who say that the findings "underscore the persistent character of obesity," akin to managing diseases like diabetes.
Patient Accounts
Users who have discontinued the medication explain a sudden resurgence of appetite.
"It was like a trigger flipping and you're instantly extremely hungry," described one woman.
This difficulty is compounded if individuals have not adopted sustainable dietary or behavioural changes during treatment.
Growing Interest
Figures show that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts stress that while GLP-1 drugs are powerful tools for weight loss, they are not a magic solution and lasting health benefits hinges on combined lifestyle management.
